PMID- 17620297
OWN - NLM
STAT- MEDLINE
DCOM- 20071214
LR  - 20161124
IS  - 1097-4652 (Electronic)
IS  - 0021-9541 (Linking)
VI  - 214
IP  - 1
DP  - 2008 Jan
TI  - TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent 
      p27Kip1 accumulation in pre-osteoclast precursors.
PG  - 117-25
AB  - Experimental evidences indicate that the TNF family member TNF-related apoptosis 
      inducing ligand (TRAIL) might be involved in modulating osteoclastic 
      differentiation. The ability of recombinant soluble TRAIL to affect bone density 
      in vivo was evaluated by using 4-week-old mice subcutaneously (s.c.) injected 
      with TRAIL for 8 days. TRAIL injection induced a significant increase of tibia 
      trabecular thickness and total bone mass in 4-week-old mice, accompanied by a 
      significant decrease of TRAP serum levels, without modulation of osteocalcin and 
      osteoprotegerin (OPG). Parallel experiments performed in vitro showed that 
      inhibition of osteoclastic differentiation, induced by treatment of human 
      peripheral blood osteoclast precursors with TRAIL, was associated to inhibition 
      of receptor activator of nuclear factor kappa B ligand (RANKL)-induced 
      accumulation of p27(Kip1). The potential role of p27(Kip1) pathway in mediating 
      the anti-osteoclastic activity of TRAIL was further suggested by in vitro gene 
      knock-down experiments performed in osteoclast precursor cultures. Taken 
      together, our data strongly suggest that recombinant TRAIL inhibits 
      osteoclastogenesis by inducing the ubiquitin-mediated degradation of p27(Kip1).
CI  - (c) 2007 Wiley-Liss, Inc.
FAU - Zauli, Giorgio
AU  - Zauli G
AD  - Department of Biomedicine, University of Trieste, Trieste, Italy. zauli@units.it
FAU - Rimondi, Erika
AU  - Rimondi E
FAU - Stea, Susanna
AU  - Stea S
FAU - Baruffaldi, Fabio
AU  - Baruffaldi F
FAU - Stebel, Marco
AU  - Stebel M
FAU - Zerbinati, Carlotta
AU  - Zerbinati C
FAU - Corallini, Federica
AU  - Corallini F
FAU - Secchiero, Paola
AU  - Secchiero P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cell Physiol
JT  - Journal of cellular physiology
JID - 0050222
RN  - 0 (Fluorescent Dyes)
RN  - 0 (Indoles)
RN  - 0 (Isoenzymes)
RN  - 0 (RANK Ligand)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Recombinant Proteins)
RN  - 0 (TNF-Related Apoptosis-Inducing Ligand)
RN  - 0 (Tnfsf10 protein, mouse)
RN  - 0 (Tnfsf11 protein, mouse)
RN  - 104982-03-8 (Osteocalcin)
RN  - 147604-94-2 (Cyclin-Dependent Kinase Inhibitor p27)
RN  - 47165-04-8 (DAPI)
RN  - EC 3.1.3.2 (Acid Phosphatase)
RN  - EC 3.1.3.2 (Acp5 protein, mouse)
RN  - EC 3.1.3.2 (Tartrate-Resistant Acid Phosphatase)
RN  - EC 3.4.- (Cathepsins)
RN  - EC 3.4.22.38 (CTSK protein, human)
RN  - EC 3.4.22.38 (Cathepsin K)
RN  - EC 3.4.22.38 (Ctsk protein, mouse)
SB  - IM
MH  - Acid Phosphatase/analysis/immunology
MH  - Animals
MH  - Cathepsin K
MH  - Cathepsins/analysis/metabolism
MH  - Cell Differentiation/*drug effects
MH  - Cell Nucleus/metabolism
MH  - Cell Separation/methods
MH  - Cells, Cultured
MH  - Cyclin-Dependent Kinase Inhibitor p27/*biosynthesis
MH  - Drug Administration Schedule
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Fluorescent Dyes
MH  - Humans
MH  - Indoles
MH  - Injections, Subcutaneous
MH  - Isoenzymes/analysis/immunology
MH  - Leukocytes, Mononuclear/cytology/*metabolism
MH  - Mice
MH  - Osteocalcin/analysis
MH  - Osteoclasts/*drug effects/physiology
MH  - RANK Ligand/*metabolism
MH  - RNA, Small Interfering/metabolism
MH  - Recombinant Proteins/administration & dosage/pharmacology
MH  - Solubility
MH  - TNF-Related Apoptosis-Inducing Ligand/administration & 
      dosage/genetics/*pharmacology
MH  - Tartrate-Resistant Acid Phosphatase
EDAT- 2007/07/11 09:00
MHDA- 2007/12/15 09:00
CRDT- 2007/07/11 09:00
PHST- 2007/07/11 09:00 [pubmed]
PHST- 2007/12/15 09:00 [medline]
PHST- 2007/07/11 09:00 [entrez]
AID - 10.1002/jcp.21165 [doi]
PST - ppublish
SO  - J Cell Physiol. 2008 Jan;214(1):117-25. doi: 10.1002/jcp.21165.